Blood Biomarker More Accurately Predicts Lung Cancer Immunotherapy Response than Tumor Biopsy
A simple blood test could be an ideal predictor of whether cancer immunotherapy will be successful for a lung cancer patient.
Read MorePosted by Andy Lundin | Jun 6, 2022 | Lung Cancer |
A simple blood test could be an ideal predictor of whether cancer immunotherapy will be successful for a lung cancer patient.
Read MorePosted by Andy Lundin | Jun 3, 2022 | Cancer, Covid 19 |
A study from the American Cancer Society evaluated the impact of the pandemic on cancer screenings nationally through population-based data.
Read MorePosted by Chris Wolski | Jun 1, 2022 | Molecular Diagnostics |
The VALID study was designed to investigate the effectiveness in determining the risk that a lung allograft is being rejected.
Read MorePosted by Andy Lundin | May 30, 2022 | Lung Cancer |
CorePath is partnering with Cizzle Biotechnology to develop and offer a proprietary early-stage lung cancer blood test for the U.S.
Read MorePosted by Chris Wolski | May 26, 2022 | Cancer |
Liquid biopsy is proving itself as both an efficacious and cost-effective way to provide a cancer diagnosis to patients.
Read More